Table 2.
Baseline characteristics and echocardiographic parameters of patients with and without trastuzumab-related cardiac dysfunction at follow-up – univariate model
| Parameter | All patients | LVEF decline ≥ 10% [No.] | LVEF decline < 10% [No.] | OR | 95% CI | p |
|---|---|---|---|---|---|---|
| Age (years) | 53.6 ± 9.0 | 53.2 ± 9.4 [22] | 52.6 ± 9.0 [56] | 1.008 | 0.954 – 1.065 | 0.7753 |
| BMI (kg/m2) | 26.1 ± 4.9 | 25.2 ± 5.2 [22] | 26.5 ± 5.4 [56] | 1.001 | 0.902 – 1.112 | 0.9805 |
| LVESV (ml) | 21.8 ± 8.0 | 17.8 ± 5.0 [22] | 22.6 ± 6.6 [56] | 0.858 | 0.774 – 0.950 | 0.0033 |
| LVEF (%) | 66.3 ± 5.8 | 70.7 ± 4.4 [22] | 64.8 ± 5.5 [56] | 1.284 | 1.128 – 1.462 | 0.0002 |
| Sm (cm/s) | 8.5 ± 1.8 | 8.1 ± 1.9 [22] | 8.6 ± 1.8 [54] | 0.945 | 0.717 – 1.242 | 0.6847 |
| NT-proBNP (pg/ml) | 79 (45-133) | 113 (61–165) [22] | 83 (53–114) [54] | 1.003 | 0.996 – 1.009 | 0.3920 |
| Em (cm/s) | 8.5 ± 2.7 | 8.4 ± 2.5 [22] | 8.5 ± 2.8 [54] | 1.000 | 0.834 – 1.200 | 0.9992 |
| LA (cm2) | 15.8 ± 3.4 | 15.6 ± 2.9 [22] | 16.1 ± 3.1 [51] | 0.945 | 0.800 – 1.116 | 0.5067 |
| E/A | 1.0 ± 0.3 | 1.0 ± 0.3 [22] | 0.99 ± 0.2 [52] | 1.194 | 0.226 – 6.299 | 0.8349 |
| HBP (%)* | 27/92 (29.3%) | 7/17 (41.1%) (22] | 20/75 (26.7%) [56] | 1.892 | 0.672 – 5.329 | 0.2273 |
Prevalence of hypertension is presented as number (proportion) of patients. NT-proBNP levels are presented as median and interquartile range. All other data are presented as mean ± SD.
LVEF: left ventricular ejection fraction(Simpson biplane method); BMI: body mass index; LVESV: left ventricular end systolic volume; Sm: peak systolic wave velocity at septal mitral position in tissue Doppler imaging; Em: early diastolic wave velocity at septal mitral position in tissue Doppler imaging; LA: left atrial area; E/A: E to A wave velocity ratio in mitral inflow pulse Doppler; HBP: high blood pressure; NT-proBNP: N-terminal pro-brain natriuretic peptide; OR: odds ratio; No.: number of patients.